Hms Capital Management, LLC Vertex Pharmaceuticals Inc Transaction History

Hms Capital Management, LLC

$202 Million
Q3 2024

A detailed history of Hms Capital Management, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Hms Capital Management, LLC holds 597 shares of VRTX stock, worth $245,158. This represents 0.14% of its overall portfolio holdings.

Number of Shares

597

Previous 597 -0.0%

Holding current value

$245,158

Previous $279,000 0.72%

% of portfolio

0.14%

Previous 0.15%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$314.42 - $351.91 $48,735 - $54,546	-155 Reduced 20.61%	597 $210,000
Q4 2022 Jan 23, 2023	SELL	$285.76 - $321.48 $5,715 - $6,429	-20 Reduced 2.59%	752 $0
Q2 2022 Jul 27, 2022	BUY	$234.96 - $292.55 $181,389 - $225,848	772 New	772 $218,000
Q3 2021 Nov 02, 2021	SELL	$181.39 - $202.99 $230,365 - $257,797	-1,270 Closed	0 $0
Q4 2020 Jan 29, 2021	SELL	$207.01 - $276.09 $888,900 - $1.19 Million	-4,294 Reduced 77.17%	1,270 $300,000
Q3 2020 Oct 20, 2020	SELL	$255.65 - $303.1 $83,341 - $98,810	-326 Reduced 5.53%	5,564 $1.51 Million
Q2 2020 Jul 31, 2020	BUY	$225.48 - $295.8 $1.1 Million - $1.45 Million	4,888 Added 487.82%	5,890 $1.71 Million
Q4 2019 Jan 29, 2020	BUY	$166.71 - $223.91 $167,043 - $224,357	1,002 New	1,002 $219,000
Q3 2019 Oct 15, 2019	SELL	$166.23 - $187.09 $166,562 - $187,464	-1,002 Closed	0 $0
Q2 2019 Jul 12, 2019	BUY	$164.61 - $190.37 $164,939 - $190,750	1,002 New	1,002 $184,000
Q1 2019 Apr 24, 2019	SELL	$163.73 - $194.7 $406,377 - $483,245	-2,482 Closed	0 $0
Q2 2018 Aug 06, 2018	BUY	$145.72 - $169.96 $361,677 - $421,840	2,482 New	2,482 $422,000

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

221M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $105B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hms Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hms Capital Management, LLC with notifications on news.

Account

Hms Capital Management, LLC Vertex Pharmaceuticals Inc Transaction History